Other Operating Income Other operating income was comprised as follows: (XLS:) Download Other Operating Income 2016 2017 € million € million 2016 figures restated Gains on retirements of noncurrent assets 64 173 Reversal of impairment losses on receivables 18 23 Reversals of unutilized provisions 122 26 Gains from derivatives 255 291 Miscellaneous operating income 328 351 Total 787 864 of which special items 115 14 Gains on retirements of noncurrent assets included an €81 million gain from the sale of trademark rights for the Vagitrol™, Benadon™, Claradol™, Transipeg™ and Colopeg™ brands and some smaller brands (Consumer Health segment). In addition, a €49 million gain was realized on the sale of capitalized transfer rights by Bayer 04 Leverkusen Fußball GmbH (All Other Segments), Germany. In the Crop Science segment, a license agreement for herbicide active ingredients with FMC Corporation, United States resulted in income of €18 million.. Miscellaneous operating income includes a receivable relating to the nonfulifillment of a purchase obligation by one of our distribution partners in the amount of €34 million (Pharmaceuticals segment). The Crop Science segment received €25 million from insurers. A further €13 million was generated by the sale of research data following patent expirations (Crop Science segment). The transfer of a database to the joint venture Cooksonia Opco LLC, United States, with Ginkgo Bioworks, Inc., United States, brought additional income of €9 million for the Crop Science segment. In addition, a claim for damages of €8 million resulting from an infringement of a patent for Yasmin™ was recorded in the Pharmaceuticals segment. Income from reversals of unutilized provisions included €9 million from the reversal of provisions for the Yasmin™ / YAZ™ litigation (2016: €104 million). Furthermore, in 2016 miscellaneous operating income included a gain of €32 million at Bayer 04 Leverkusen Fußball GmbH from the sale of non-capitalized transfer rights (All Other Segments). In the Crop Science segment, milestone payments led to income of €21 million. In the Pharmaceuticals segment, a €14 million compensation payment was received in connection with the closure of the production site in Putuo, China. A €10 million gain (All Other Segments) was incurred on the sale of the BAYQUIK™ technology to Chemetics, Inc., Canada (Corporate Functions segment).